Press Releases

11.04.2022
Iveric Bio to Present at Upcoming Investor Conferences
11.03.2022
Iveric Bio Announces Submission of First Part of NDA for Rolling Review of Avacincaptad Pegol for the Treatment of Geographic Atrophy
11.03.2022
Iveric Bio Reports Third Quarter 2022 Operational Highlights and Financial Results
11.02.2022
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10.27.2022
Iveric Bio to Report Third Quarter 2022 Financial Results and Host Conference Call on Thursday, November 3, 2022
10.04.2022
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09.27.2022
Iveric Bio to Present Top-line Results for Avacincaptad Pegol from Phase 3 GATHER2 Clinical Trial in Geographic Atrophy at AAO 2022 Annual Meeting
09.07.2022
Iveric Bio to Present at Upcoming Investor Conferences
09.06.2022
Iveric Bio Announces Positive Topline Data from Zimura® GATHER2 Phase 3 Clinical Trial in Geographic Atrophy
09.02.2022
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)